LNTH | tickerfilter.com

Fundamental analysis

65%

Profitability 66%

Dept financing 50%

Liquidity 24%

Performance 78%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

5.25%

1 Month

19.58%

3 Months

27.43%

6 Months

46.49%

1 Year

-19.69%

2 Year

20.62%

Key data

Stock price

$78.84

P/E Ratio

18.89

DAY RANGE

$74.33 - $79.51

EPS

$3.46

52 WEEK RANGE

$47.25 - $111.29

52 WEEK CHANGE

-$21.54

MARKET CAP

4.413 B

YIELD

N/A

SHARES OUTSTANDING

64.606 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

07-30-2025

BETA

0.46

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,259,620

AVERAGE 30 VOLUME

$948,413

Company detail

CEO: Mary A. Heino
Region: US
Website: lantheus.com
Employees: 700
IPO year: 2015

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates disease burden of prostate cancer by quantifying the hotspots on bone scans.

LNTH - Lantheus Holdings, Inc.